191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

S. Peters; S. Antonia; S. B. Goldberg; J. V. Heymach; E. S. Kim; K. Nakagawa; V. Papadimitrakopoulou; P. Mukhopadhyay; S. McIntosh; N. A. Rizvi

doi:10.1016/S1556-0864(16)30300-8

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

S. Peters, S. Antonia, S. B. Goldberg, J. V. Heymach, E. S. Kim, K. Nakagawa, V. Papadimitrakopoulou, P. Mukhopadhyay, S. McIntosh, N. A. Rizvi

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Original language	English (US)
Pages (from-to)	S139-S140
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30300-8
State	Published - Apr 2016

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/S1556-0864(16)30300-8

Cite this

Peters, S., Antonia, S., Goldberg, S. B., Heymach, J. V., Kim, E. S., Nakagawa, K., Papadimitrakopoulou, V., Mukhopadhyay, P., McIntosh, S., & Rizvi, N. A. (2016). 191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. Journal of Thoracic Oncology, 11(4), S139-S140. https://doi.org/10.1016/S1556-0864(16)30300-8

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. / Peters, S.; Antonia, S.; Goldberg, S. B. et al.
In: Journal of Thoracic Oncology, Vol. 11, No. 4, 04.2016, p. S139-S140.

Research output: Contribution to journal › Article › peer-review

Peters, S, Antonia, S, Goldberg, SB, Heymach, JV, Kim, ES, Nakagawa, K, Papadimitrakopoulou, V, Mukhopadhyay, P, McIntosh, S & Rizvi, NA 2016, '191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC', Journal of Thoracic Oncology, vol. 11, no. 4, pp. S139-S140. https://doi.org/10.1016/S1556-0864(16)30300-8

Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K et al. 191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. Journal of Thoracic Oncology. 2016 Apr;11(4):S139-S140. doi: 10.1016/S1556-0864(16)30300-8

@article{748f8879cfa74728ab8cb3b333a90e55,

title = "191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC",

author = "S. Peters and S. Antonia and Goldberg, {S. B.} and Heymach, {J. V.} and Kim, {E. S.} and K. Nakagawa and V. Papadimitrakopoulou and P. Mukhopadhyay and S. McIntosh and Rizvi, {N. A.}",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30300-8",

language = "English (US)",

volume = "11",

pages = "S139--S140",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "4",

}

TY - JOUR

T1 - 191TiP

T2 - MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

AU - Peters, S.

AU - Antonia, S.

AU - Goldberg, S. B.

AU - Heymach, J. V.

AU - Kim, E. S.

AU - Nakagawa, K.

AU - Papadimitrakopoulou, V.

AU - Mukhopadhyay, P.

AU - McIntosh, S.

AU - Rizvi, N. A.

PY - 2016/4

Y1 - 2016/4

UR - http://www.scopus.com/inward/record.url?scp=85017741726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017741726&partnerID=8YFLogxK

U2 - 10.1016/S1556-0864(16)30300-8

DO - 10.1016/S1556-0864(16)30300-8

M3 - Article

AN - SCOPUS:85017741726

SN - 1556-0864

VL - 11

SP - S139-S140

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this